LEM-PASS: Safety follow-up after treatment with alemtuzumab (Sponsor Sanofi)
CLAD-CROSS: A prospective study of safety and efficacy when switching to cladribine (Sponsor Merck)
COMB157G23101: A prospective study of efficacy and safety when switching from dimethylfumarate or fingolimod to ofatumumab (Sponsor Novartis)
GEMINI: Double blind, randomized study comparing BTKi-inhibitor with teriflunomide in RRMS (Sponsor Sanofi)
HERCULES: Double blind, randomized study comparing BTKi-inhibitor with placebo in SPMS (Sponsor Sanofi)
Recent publications
Andreassen S, Lindland EMS, Beyer MK, Solheim AM, Ljøstad U, Mygland Å, Lorentzen ÅR, Reiso H, Bjuland KJ, Pripp AH, Harbo HF, Løhaugen GCC, Eikeland R(2022) Assessment of cognitive function, structural brain changes and fatigue 6 months after treatment of neuroborreliosis J Neurol(in press) DOI 10.1007/s00415-022-11463-7, PubMed 36380166
Cappelletti C, Eriksson A, Brorson IS, Leikfoss IS, Kråbøl O, Høgestøl EA, Vitelli V, Mjaavatten O, Harbo HF, Berven F, Bos SD, Berge T(2022) Quantitative proteomics reveals protein dysregulation during T cell activation in multiple sclerosis patients compared to healthy controls Clin Proteomics, 19(1), 23 DOI 10.1186/s12014-022-09361-1, PubMed 35790914
Rise HH, Brune S, Chien C, Berge T, Bos SD, Andorrà M, Valdeolivas IP, Beyer MK, Sowa P, Scheel M, Brandt AU, Asseyer S, Blennow K, Pedersen ML, Zetterberg H, de Schotten MT, Cellerino M, Uccelli A, Paul F, Villoslada P, Harbo HF, Westlye LT, Høgestøl EA(2022) Brain disconnectome mapping derived from white matter lesions and serum neurofilament light levels in multiple sclerosis: A longitudinal multicenter study Neuroimage Clin, 35, 103099 DOI 10.1016/j.nicl.2022.103099, PubMed 35772194